Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 4;22(1):869.
doi: 10.1186/s13063-021-05675-x.

A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial

A Abayomi  1 , A Osibogun  2 , O Ezechi  3 , K Wright  4 , B Ola  4 , O Ojo  5 , Y Kuyinu  4 , E Zamba  6 , H Abdur-Razzaq  1 , O A Erinoso  5 , S E Anya  7
Affiliations

A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial

A Abayomi et al. Trials. .

Abstract

Background: The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was first identified in Wuhan, Hubei, China, in December 2019. It was recognized as a pandemic by the World Health Organization on 11 March 2020. Outbreak forecasting and mathematical modelling suggest that these numbers will continue to rise. Early identification of effective remedies that can shorten the duration and severity of illness is critical for Lagos State, which is the epi-centre of the disease in Nigeria.

Methods: This is a multi-centre, randomized, double-blind placebo-controlled superiority trial. The study investigates the efficacy of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir added on to standard of care compared to standard of care only in patients with COVID-19 disease. The primary outcome is the clinical status of patients measured using a 7-point ordinal scale at day 15. Research participants and clinicians will be blinded to the allocated intervention. Outcome measures will be directly assessed by clinicians. Statistical analysis will be done by a team blinded to the identity and allocation of research participants. Data analysis will follow intention-to-treat methods, using R software.

Discussion: The current study is of strategic importance for Lagos State in potentially curbing the health, social and economic burden of COVID-19 disease. Should the current study demonstrate that either of the three intervention drugs is more efficacious than standard therapy alone, the State Ministry of Health will develop an evidence-based guideline for the management of COVID-19 in Lagos State. The findings will also be shared nationally and with other states which may lead to a standardized national guideline for the treatment of COVID-19 in Nigeria.

Trial registration: Pan African Clinical Trials Register PACTR202004801273802 . Registered prospectively on April 2, 2020.

Keywords: 2019-nCoV; COVID-19; Chloroquine; Hydroxychloroquine; Lagos; Lopinavir/ritonavir; Nigeria; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Schematic diagram showing the timeline for key processes in LACTT
See this image and copyright information in PMC

References

    1. World Health Organization . Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-19) 2020.
    1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19. 2020. [Internet]. [cited 2020 Mar 25]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re....
    1. Johns Hopkins CSSE. Coronavirus COVID-19 global cases [Internet]. [cited 2020 July 20th]. Available from: https://coronavirus.jhu.edu/map.html
    1. World Health Organization . Coronavirus disease 2019 (COVID-19) situation report –163. 2020.
    1. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet Lond Engl. 2020;395(10225):689–697. doi: 10.1016/S0140-6736(20)30260-9. - DOI - PMC - PubMed

Publication types

Grants and funding

LinkOut - more resources